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EDITORIAL
Calcimimetics in action
The recent identification of a calcium receptor in the parathy-
roid gland [1] has provided important new understanding of a
variety of relatively uncommon metabolic disorders. Genetic
defects in this receptor clearly play an important role in familial
hypocalciuric hypercalcemia [2], in which the receptor is less
responsive to calcium, and in various hereditary forms of hypo-
parathyroidism [3], in which responsiveness to calcium is in-
creased and parathyroid hormone (PTH) secretion is suppressed
by calcium levels substantially below normal.
While these discoveries have been enormously exciting and
provocative, for the clinician the development of agents that
activate the receptor independent of calcium (calcimimetics)
provides a therapeutic modality with wide-ranging possibilities.
Scientists at NPS Pharmaceuticals have developed a compound,
R-568, given by mouth, that activates the calcium receptor to
suppress PTH secretion. It also binds to several other sites of
interest, specifically the thyroid C cell and the renal tubule. At
these latter sites it may also simulate the effects of calcium itself
by stimulating calcitonin release from C cells and decreasing renal
tubular calcium reabsorption (though there is as yet no direct
evidence of an effect at the renal tubule). For the first time, then,
a potential therapy that decreases PTH secretion does not result
in an increase in serum calcium.
The focus of animal studies to explore these effects has been on
PTH levels and the safety of effective doses. Numerous studies in
rats and other species have been conducted that do not show any
unusual toxicity. The study by Wada et al in the current issue of
Kidney International [4] extends studies of R-568 to a condition of
particular interest to nephrologists, renal osteodystrophy. After
inducing renal failure and hyperparathyroidism in rats, the inves-
tigators assessed the ability of R-568 both to suppress PTH
secretion and to improve bone histology. The results met expec-
tations, with improvement not only in PTH levels and bone
histology, but also in bone strength.
Of course, the questions clinicians will want answered is: are
these results achievable in humans as well? The answer is a
qualified affirmative. Reports of single-dose studies in normal
subjects, patients with primary hyperparathyroidism and patients
with secondary (renal) hyperparathyroidism have been published
recently [5, 6]. In all cases, over a wide range of oral doses, PTH
secretion was suppressed. Larger doses produced greater suppres-
sion and the effect persisted longer. No side-effects have been
observed, but of course, these preliminary studies in fewer than
100 patients cannot be presumed to address the safety issues.
Larger studies of longer duration will be needed to delineate these
issues as well as define the clinical role of calcimimetic agents.
Use of these agents is likely to differ in the two patient
populations investigated so far. In primary hyperparathyroidism
the drug should provide a medical equivalent to surgery. For
patients in whom surgery may be risky or the benefits of it unclear,
the potential exists to suppress PTH production to any degree
desired and to reverse the suppression at any point. Presumably,
clinicians will want to suppress PTH sufficiently to control hyper-
calcemia and/or hypercalciuria. Whether suppression to a greater
degree is desirable remains to be demonstrated.
In patients with renal failure and secondary hyperparathyroid-
ism, therapy will be more complicated than in patients with
primary hyperparathyroidism. In patients with the secondary
hyperparathyroidism of renal failure the calcium is likely to fall,
perhaps too greatly, if a calcimimetic is used as the sole therapy.
Indeed, successful suppression of PTH should lead to this out-
come (as currently occurs with parathyroid surgery in such
patients). Therefore, clinicians will need to regulate calcium and
calcitriol intake to maintain calcium when a calcimimetic is
prescribed. At first blush this seems to complicate therapy. In my
opinion, it actually simplifies treatment, since our current medical
approach to this condition is limited by the development of
hypercalcemia. Using one agent to regulate PTH and another to
control calcium will produce better control of treatment strate-
gies.
Calciphylaxis and parathyromatosis, two rare complications of
calcium metabolism in renal failure that are exceedingly frustrat-
ing to treat [7], may respond to calcimimetic therapy. Calciphy-
laxis does not always respond to parathyroid surgery. The use of
a calcimimetic, by duplicating the effect of such surgery, should
identify patients who will respond to it (or provide an alternate
therapy for those in whom the operative procedure is deemed
risky). Currently we have no treatment for parathyromatosis.
In summary, the development of calcimimetics presents a
remarkable therapeutic potential for a variety of difficult clinical
problems. I look forward to the continued clinical evaluation of
this class of drugs and their ultimate addition to extant therapeutic
efforts.
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